The cost of generating a quality-adjusted life year (QALY) within a National Health Service provides an approximation of the average opportunity cost of funding decisions. This information can be used to inform a cost-effectiveness threshold. The aim of this paper is to estimate the cost per QALY at the Spanish National Health Service. We exploit variation across 17 regional health services and the exogenous changes in expenditure that took place as a consequence of the economic crisis over 5 years of data. We conduct fixed effect models and use an instrumental variable approach to test for potential remaining endogeneity.
| INTRODUCTION
Cost-effectiveness analysis results are usually summarised by the incremental cost-effectiveness ratio (ICER), defined as the incremental cost divided by the incremental effectiveness of two competing alternatives, using quality-adjusted life years (QALYs) as the measure of effectiveness. However, cost-effectiveness analysis evidence supplied as the incremental cost per QALY gained of competing health technologies is not enough to ultimately make adoption or otherwise recommendations on the basis of cost-effectiveness. For decision making, the ICER of a technology needs to be compared with a value that indicates the maximum amount considered acceptable to be paid for health gains in the health system, that is, the cost-effectiveness threshold. This value is unknown in most health care systems.
A recent review of studies estimating a cost-effectiveness threshold identified 38 studies (Vallejo-Torres et al., 2016) . The studies were driven by different views as to what the threshold ought to represent. The two main conceptual perspectives are that the threshold should reflect (a) society's monetary valuation of health gains or (b) the opportunity cost resulting from the disinvestment required to adopt a new technology (Baker et al., 2011) . A consultation among experts conducted in Spain concluded that both approaches should be explored in order to inform a cost-effectiveness threshold in Spain (García-Lorenzo et al., 2015) . Some authors have, however, emphasised that when facing a fixed health care budget, information on the opportunity cost of funding decisions is most relevant as it provides a basis to assess whether the health expected to be gained from the use of a new technology exceeds the health expected to be forgone as other services are necessarily displaced (Claxton et al., 2015) .
The aforementioned literature review (Vallejo-Torres et al., 2016) and the consultation process (García-Lorenzo et al., 2015) were part of a project commissioned by the Spanish Ministry of Health to provide evidence on how to estimate a cost-effectiveness threshold for the Spanish National Health Service (SNHS). Following these, this paper focuses on a first empirical estimation of the opportunity cost of health care funding decisions in Spain.
To do so, this study estimates the marginal cost per QALY at which the SNHS currently operates on average. The cost per QALY reveals how much health is lost when services currently provided by the system are displaced and has been suggested as a proxy of the average opportunity cost value that can be used to inform a cost-effectiveness threshold (Claxton et al., 2015) .
We use data across the 17 regional health services that compose the SNHS over the period [2008] [2009] [2010] [2011] [2012] , when the health budget experienced considerable exogenous cuts due to the economic crisis. Although health spending per capita grew at an annual 4.1% rate between 2003 and 2008, per capita spending on health decreased at a 1.2% annual rate between 2008 and 2013 (European Commission, 2016 as a result of the austerity policies adopted in this period. These policies included, among other measures, cuts in health care staff levels and a reduction in pharmaceutical spending by increasing copayments and excluding previously covered drugs (Gallo and Gené-Badia, 2013) . We exploit variations between regions and over time to estimate the impact of health spending on health outcomes, measured as quality-adjusted life expectancy (QALE). The estimated effect is then translated into the cost per QALY for the SNHS, providing a measure of the scale of the opportunity cost of health care funding decisions in Spain.
Although the aim of this work is on the estimation of a cost-effectiveness threshold, the analyses undertaken in this paper inform a broader issue regarding health effects related to changes in health care expenditure.
| Previous studies
Measuring the marginal cost per QALY on average across a health care system involves estimating the impact of health care expenditure on health outcomes, that is, the health spending elasticity of health. This has been the focus of several previous studies. Gallet and Doucouliagos (2015) conducted a quantitative review of 65 studies estimating the relationship between health outcomes and health expenditure. The authors estimated metaregressions on the health spending elasticity using 885 estimates: 629 observations for mortality and 256 observations for life expectancy (LE). The results showed that "spending elasticity for mortality is in the neighborhood of -0.10, whereas it is roughly equal to 0.02 for life expectancy".
There are also a series of studies that have estimated the cost per life year (LY) on the basis of the estimated health spending elasticity. For example, Lichtenberg (2004) estimated a cost of $11,000 per LY in the United States using time series data from 1960 to 1997. In Spain, Puig-Junoy and Merino-Castelló, 2004 applied a similar methodology using health spending and LE at birth from 1960 to 2001 and estimated a cost per LY of under 13,000€.
Some studies have adjusted the estimated impact on mortality to account for health-related quality of life (HRQoL) in order to approximate the estimation to the marginal cost of a QALY. For example, Smith (2008, 2012) measured the cost per QALY for specific diseases using administrative data for primary care trusts in England. The most recent of these papers used spending data from 2005/06 for five diseases. Their results ranged from £12,593 per QALY for cardiovascular diseases to £47,069 per QALY for diabetes. Claxton et al. (2015) used a similar approach but provided an estimate for each of the 23 disease programmes using expenditure data from 2008/09 and combined the disease-specific values to arrive at a central estimate of £12,936 per QALY in England.
| Spanish health financing system
The SNHS experienced a decentralisation process that started in the early 1980s and was completed in 2002, when all 17 regions, named autonomous communities (ACs), that form the country were responsible for planning and delivery of their own health services. Therefore, the SNHS consists of 17 different regional health services that hold over 92% of the overall national health budget; the rest corresponds to central government administration services.
Health care is financed through general taxation collected by both the central and regional governments. The central government then allocates a budget across regions to meet the provision of the following public services for which ACs are responsible: health, education, social services, and other general services such as culture, housing, and infrastructure. There is an allocation mechanism to compute the corresponding shares transferred from the central administration to each region.
1 The allocation mechanism is based on a set of weighting indicators that take into account demographic and geographical factors (De la Fuente, 2015) . On the basis of these factors, the central government allocates a total budget across regions, and each region then decides how to distribute their budget across the public services for which they are responsible.
Over the period of analysis, health spending was substantially reduced in Spain as a consequence of the economic crisis and subsequent health budget cuts and stringent requirement for ACs to meet deficit reduction goals. As a result, health spending decreased by nearly 10% between 2009 and 2012. 
• H jt is the population health variable observed for region j at time t, • Exp t − 1 is the lagged health expenditure variable of region j in year t − 1, • X jt − 1 is a set of other lagged attributes of region j in year t − 1, • γ t is a fixed effect for year t, • μ j is a fixed effect for region j, and • ε it is a disturbance term.
H and Exp have been log transformed, and therefore, the β parameter estimate can be interpreted as an elasticity. The lag structure allows for the fact that the impact on health is not likely to occur contemporaneously with expenditure, as a delay in accruing a health benefit is expected. We compute heteroskedasticity-robust standard errors and adjust for clustering at the region level.
| IV models
Fixed effects are used as a means of addressing endogeneity. The regional indicators control for time-invariant differences between regions, whereas the year indicators control for factors that vary uniformly over time across all regions. However, these models may not capture all sources of variation within regions and years that correlate with expenditure and health outcomes, such as unobserved factors that vary both across regions and over time; in that case, some degree of endogeneity might remain. As health spending is partly determined by the level of health care needs, which are correlated with health outcomes, we expect models that do not account for potential endogeneity to show a downward bias in the relationship between expenditure and health outcomes. We use an instrumental variable (IV) approach to test and address for this potential endogeneity problem. The performance of the IV estimators critically relies on the validity of the instruments, which have to satisfy two properties: They have to be highly correlated with the variables being instrumented (relevance of instruments), and they must be uncorrelated with the error term of the health outcomes equation conditional on the other covariates in the model (orthogonality requirement). We test for the relevance property based on an F test of the significance of the instruments in the first-stage equation. The orthogonality requirement cannot be formally tested and mainly relies on face validity arguments. If a larger number of instruments than endogenous variables are available, then a test of overidentifying restrictions can partly explore the validity of such set of instruments (e.g., Hansen-Sargan test). We test for exogeneity using auxiliary regressions (Davidson & MacKinnon, 1993) . If we fail to reject the null hypothesis of exogeneity then, assuming the instruments are valid, OLS models yield consistent parameter estimates.
We use the percentage of total expenditure assigned to health in each region as an instrument to test for the potential remaining endogeneity. As previously mentioned, the central government allocates to each AC a total budget to finance the public services they are responsible for, and ACs decide how much of that budget is assigned to health. Variations in this variable across the period of analysis would reflect ACs' response to central government cuts in public expenditure. For instance, some regions might be able to maintain per capita expenditure on health over this period of austerity measures by increasing the percentage of their total budget that is assigned to health. This variable is thus expected to influence how much a region spends on health per capita and should capture variations in health expenditure that result from budget cuts, that is, the exogenous changes in expenditure on health. The percentage of total expenditure assigned to health over time might also be correlated with changes in population health factors. However, our models include a comprehensive list of indicators (see below) controlling for this potential correlation, consisting of demographics, health, socio-economic, and environmental variables, as well as regional and year effects as we detail below.
| Data

| Health variable
Our measure of health is QALE. QALE provides a comprehensive measure of health outcomes that is relevant for all SNHS activities and allows the estimation of the impact of expenditure on mortality as well as on HRQoL. LE by region and year are computed by the Office of National Statistics in Spain on the basis of mortality rates published in Life Tables. 3 We combine the information on LE with information on HRQoL to adjust LE by health status. The most widely used methodology to apply this adjustment is the Sullivan (1971) method used to compute disability-free life expectancies applying a dichotomous disability variable. We use a similar approach but applied data on EQ-5D weights to undertake this adjustment. This allows us to create an LE variable adjusted for HRQoL on a QALY scale. To do this, we adjust the number of years lived in each age range according to Life Tables, multiplying them by the average EQ-5D scores by age and gender (Gaminde & Roset, 2001) .
QALE values provide the expected number of healthy years that individuals of a certain age are expected to live. We conducted regressions of QALE at each age (QALE x , x = at birth, 1 year, 5 years, 10 years, …, 95 years). In addition to estimating the impact of health expenditure on QALE at given ages, we also estimated the impact on the average QALE of the population. The latter is computed as follows, where w x is the share of the population in age group x (Lichtenberg, 2004) :
| Quality of life variable
The only source of Spanish nationally representative EQ-5D data are the Spanish Health Survey (SHS) conducted in 2011/12. There are two other surveys, the SHS in 2006/07 and the European Health Interview Survey (EHIS) conducted in Spain in 2009/10, which did not include EQ-5D but included a series of other health and socio-economic indicators. We use these surveys 4 to generate predicted EQ-5D values that allow us to create a time-variant HRQoL indicator used to adjust LE information. EQ-5D models are stratified by gender and age groups (15-44, 45-64, and 65 or more years). In each case, we use generalised linear models with log link function and Gaussian variance on HRQoL decrements, that is, on 1 minus reported EQ-5D values. The models take the form
• EQ5D i is the EQ-5D score of individual i, • H i is a set of health-related indicators of individual i, • Soc i is a set of socio-economic characteristics of individual i, and • ε i is a disturbance term.
The predictors included in the models are age; self-assessed health; whether or not the individual has one of the seven long-standing illnesses that were included across all surveys; and whether or not the respondent experienced no limitations or moderate or severe limitations on daily activities in the past 6 months.
Individuals might report different levels of EQ-5D due to differences in reporting behaviour not related to differences in their underlying health status but due to, for instance, their socio-economic characteristics. Therefore, we also include in these models a series of socio-economic indicators that consist of nationality, marital status, educational attainment, and economic activity. When predicting EQ-5D scores, we fix the socio-economic variables at the sample mean value with the aim of removing any socio-economic-related reporting bias. As a result, our HRQoL indicator depends on the purged effect of health problems on HRQoL and on the varying levels of these indicators across regions and across time.
We then compute the HRQoL indicator as the mean value of the predicted EQ-5D scores by region and year for each gender and age group. EQ-5D estimates constructed using SHS 2006/07 were used to adjust LE data in 2008, estimates using data from EHIS 2009/10 were linked to LE for 2009 and 2010, and the remaining years (2011) (2012) (2013) were linked to SHS 2011/12 estimates. EQ-5D data on individuals younger than 15 years are not available in the SHS; thus, the values estimated in the youngest available age group (15-44) were used for these individuals.
| Expenditure data
Our measure of spending is health expenditure per person per year. We use total actual public health expenditure by region and by year as provided by the Ministry of Health statistics database. 5 We compute expenditure per capita by dividing total expenditure by the size of the population in the corresponding year according to the population statistics published by the Office of National Statistics in Spain. Data were taken from 2008 to 2012 and adjusted for inflation using gross domestic product deflator estimates for Spain provided by the World Bank. 6 Values are expressed in €2012.
| Other indicators
We include a comprehensive list of variables capturing region-and time-variant differences in needs for health care resources. For this, we assemble a unique dataset of demographic, socio-economic, health, and environmental factors (see Appendix A). Demographic variables include information on the size of the population; the proportion of males; and the proportion by age group. We also include a comprehensive list of health variables that aim to control for health spending needs over and above age and gender characteristics. These consist of prevalences of major diseases proxied by age-adjusted hospitalisation rates per 10,000 individuals by International Classification of Diseases-Ninth Revision groups; individuals on incapacity benefits; individuals with disability; number of traffic accident victims; individuals on retirement benefits; and proportion of smokers. A series of regional socio-economic indicators were also included that consist of gross domestic product per capita; unemployment rate; poverty risk; individuals educational attainment; and number of immigrants by country of origin. We also aim to control for unavoidable variations in health spending such as differences on the cost of providing care proxied by the cost of floor space in squared metres and mean salaries. Finally, we take into account the number of individuals in each region who have health insurance cover provided by other public administrations. We take a full model approach by including this comprehensive list of covariates and fixed effect indicators that are expected and aimed to control for the factors affecting the relationship between health expenditure and health outcomes. The analysis of the impact of each individual covariate on health outcomes is beyond the aim of this study.
| Cost per QALY transformation
Equation 1 assumes that, in the long run, permanent changes in health expenditure per year are associated with permanent changes in LE. As Lichtenberg (2004) pointed out, a permanent increase in annual health spending would be required to achieve a permanent longevity increase. 7 In our setting, this implies that the β coefficient estimated in Equation 1 pertains to the (quality-adjusted) longevity impact of a sustained unit increase in health expenditure per capita. Therefore, to estimate the cost per LY, we compute the ratio of the permanent change in health expenditure and the permanent change in QALE. The change in health expenditure is the cost of a 1€ increase in health expenditure in every age of the current cohort, which is 1€ times the remaining LE of the population at a given age. The change in QALE is made up of changes in the mortality risks individuals face in every age of the cohort, which it is given by the estimated elasticity evaluated at the sample means to arrive at the average marginal effect. Therefore, the cost per QALY is computed as the ratio of a 1€ increase times the LE of the population at a given age, divided by the associated marginal effect on QALE.
We compute the cost per QALY at every given age, as well as the cost per QALY for the average QALE of the population. In order to combine the age-specific estimations, we compute (a) the mean cost per QALY across the age-specific models, weighted to account for the population size of each age group in Spain, and (b) the overall cost per QALY as the ratio of the sum of the incremental total health expenditures across age groups and the sum of the incremental health gains in each age group using the following formulae:
• n x is the population size of age group x,
• ΔExp x is the incremental annual expenditure in age group x,
• ΔQALE x is the incremental effect on QALE in age group x, and • LE x is LE of age group x.
3 | RESULTS 
| Descriptive statistics
| Quality of life models
The coefficients of the health and socio-economic variables included in the regression models of EQ-5D decrements stratified by age and gender using the SHS 2011/12 are presented in Table 2 . Some covariates are excluded from the regression models due to small numbers or counterintuitive signs due to collinearity. Mean values of the included covariates across the SHS 2006/07, EHIS 2009/10, and SHS 2011/12 used to derive out-of-sample predictions are also shown in Table 2. 7 Lichtenberg (2004) estimates the so-called long-run elasticity of life expectancy with respect to health spending using time series. In his model, life expectancy is regressed against its own lagged value and current health expenditure, and the long-run elasticity is computed as the ratio of the effect of annual expenditure divided by 1 minus the effect of lagged life expectancy. Our model specification is different in that we include year and region fixed effects-instead of lagged QALE-to estimate within-region changes in health outcomes. A very similar result was obtained when we applied Lichtenberg's approach and introduced lagged QALE in the models. Table 3 summarises the main model results. We run separate models for the average QALE of the population as well as for QALE at given ages. The effect of the control variables in the model of average QALE are presented in Appendix B. The same covariates were included in every model.
| Health expenditure models
The first row in Table 3 shows the results for the model of the average QALE of the population. The estimated elasticity of 0.0681 (second column) indicates that a 1% increase in per capita annual health expenditure increases average QALE in 0.0681%. This is a positive and statistically significant effect of health expenditure on population health. When evaluating this result at sample means, this finding implies that, on average, an increase in 1€ in health expenditure per person per year leads to a QALE increase of 0.0018 years or 0.65 days (third column). In other words, a 10€ extra spending per person per year in health would be related to, on average, an increased LE of 6.5 days in perfect health.
When looking at QALE models at given ages, the estimated effects of health spending are positive in every case and statistically significant at early ages as well as in the oldest age group. The results also show that expenditure elasticity appears to increase with age, and therefore, the estimated cost per QALY is lower as the individual ages (Figure 1 ).
| Cost per QALY transformation
The fifth column in Table 3 shows the cost per QALY for the average population as well as the cost per QALY at different ages. These results are shown graphically in Figure 1 . The cost per QALY for the average population is estimated in 24,870€ (= 1€ * 44.31/0.0018; fifth column). The mean cost per QALY following from the age-specific models is estimated in 22,164€. The overall cost per QALY following Equation 4 is 21,752€.
| IV Models
The last two columns of Table 3 show the results for the IV models. There is a strongly significant correlation between the instrument and the potentially endogenous variable (F test 32.71; p-value < .0001), indicating that the instrument meets the relevance requirement. We cannot empirically test for the orthogonality criterion; the partial test of overidentification cannot be conducted as the number of instruments available is not higher than the potentially endogenous variables. Note. Negative coefficients mean the variable increases health-related quality of life and vice versa. Some covariates are excluded from the regression models due to small numbers or counter-intuitive signs due to collinearity (dashes).
*p-value < .10. **p-value < .05.
***p-value < .01.
The IV results are very similar to, and as expected slightly larger than, the OLS model estimates (elasticity = 0.0731; cost per QALY = 23,158€). Assuming that the instrument is valid, the exogeneity tests fail to reject the exogeneity of health expenditure in every model. Therefore, OLS estimates presented in the previous section are preferred to the IV model estimates. Based on the population-weighted mean of the cost per QALY across age groups.
b Based on the ratio between the sum of incremental annual health expenditures across age groups and the sum of the incremental annual health gains in each age group (Equation 4).
*p-value < .10. **p-value < .05. ***p-value < .001.
FIGURE 1
Cost per quality-adjusted life year (QALY) and elasticities at given ages 3.6 | Additional analyses Table 4 presents additional analyses that were conducted to explore a series of issues. For simplicity, we use the model of average QALE as the base case to allow comparisons across different model specifications. First, we tested for different functional forms of the health expenditure variable by including second-and third-order polynomial functions (without log transformation). The squared and cubic terms were nonsignificant.
Ministry of Health statistics on health expenditure included a note indicating that Cantabria health spending information included for the first time in 2012 payments made through the "extraordinary supplier payment" mechanism. Excluding this payment implies a reduction in health spending per capita from 1,766€ to 1,333€ in Cantabria in 2012, in line with the pattern observed in other regions. This, however, does not have a substantial effect on the overall model results. The estimated marginal cost of a QALY using this adjusted figure for Cantabria is 22,674€.
We experimented with applying a 3% discount rate to QALE gains and to the corresponding lifetime health spending investment, assuming that health gains are proportional over time and linear with respect to increases in expenditure. The cost per QALY using this approach was estimated to be 24,506€.
In addition, Table 4 shows how the estimated impact of expenditure on QALE as increasingly more sets of covariates are included in the model. Controlling only for age and gender characteristics yields an observed negative relationship between expenditure and health outcomes. However, after controlling for differences in underlying health factors, the relationship between spending and QALE becomes positive. The estimated effect increases as controls for socio-economic, environmental, and population covered by insurance are added.
We conducted an analysis that uses the squared root of the population size of each region as a weighting factor in the regression (Solon, Haider, & Wooldridge, 2015) . The estimated coefficient remained significant and yielded a cost per QALY value of 31,737€. We discuss the appropriateness of weighting in the next section.
We also estimated the impact of expenditure on QALE without allowing for a lag between spending and health outcomes. We found that in this case the effect of expenditure is considerably smaller and nonsignificant, suggesting that there is a delay in accruing health benefits related to higher spending. This might also reflect a larger degree of endogeneity between contemporaneous health and health spending. Employing a 2-year period lag also yielded a nonsignificant effect.
Finally, we estimated a health spending elasticity for average LE of 0.0212 and for LE at birth in 0.0112 (Table 4) . This was found to be in line with previous research (Gallet & Doucouliagos, 2015) . Note. ME = marginal effect; QALE = quality-adjusted life expectancy; QALY = quality-adjusted life year; HRQoL = health-related quality of life; LE = life expectancy; N/A = not applicable.
***p-value < .001.
| DISCUSSION
In this study, we provide an estimate of the marginal cost of a QALY in the SNHS. This value approximates the average opportunity cost of incorporating health technologies in the SNHS when disinvestment is required to fund new interventions. The figure was estimated to lie between 22,000€ and 25,000€ per QALY, depending on whether we consider the estimates provided by different age groups or the value derived from the average population model, respectively. The methodology applied in this paper builds on previous work by Claxton et al. (2015) . However, in this study, we used panel data on expenditure and health outcomes for the same regions over multiple time periods, which allows us to control for the effects of unobservable factors based on fixed effect specifications. Moreover, Claxton et al. (2015) estimated the effect of health spending on mortality alone and assumed that HRQoL improves in proportion to the estimated mortality improvement. In this paper, we have used a health outcome variable capturing differences in mortality and morbidity in order to directly estimate the impact of health expenditure on mortality as well as on HRQoL. On the other hand, information on health spending across disease programmes is not available in Spain, and therefore, disease-specific models as conducted in Claxton et al. (2015) were not feasible. Although our approach does not allow for the flexibility of disease models, it provides us with an average estimate across the overall SNHS, which is the ultimate aim of this research. It is also worth noting that our period of analysis, characterised by disinvestments across all regions, provides us with a potentially more accurate estimate of the amount of health displaced by disinvestment, that is, the opportunity costs, than estimates based on periods of growing spending.
We acknowledge a series of limitations of this study. First, there are data restrictions, especially with respect to HRQoL data collected only in 2011/12. We attempted to overcome this limitation by generating predicted values based on the impact that health problems have on HRQoL purged from reporting bias and the varying degree of these health problems over time and across regions. Although this approach might provide more appropriate HRQoL indicators than that from observed raw data, we had to rely on the estimated effects based on a single year of EQ-5D data. Routinely collecting EQ-5D information in health surveys would help addressing this limitation. Second, the exogeneity test indicating that spending is not endogenous relies on the validity of the instrument we used. Although the instrument met the relevance requirement, the orthogonality criterion could not be formally tested, yielding some uncertainty about the validity of the instrument. However, variations in expenditure exploited in this study are mainly driven by exogenous changes in health spending due to the economic crisis and subsequently budget cuts. This facilitates the identification of the causal effect of expenditure on health outcomes and reinforces the finding of a lack of endogeneity bias in our analysis. Third, the transformation we applied to translate the spending elasticity for QALE into a cost per QALY is not straightforward and implies that a permanent increase in annual health spending is required to achieve the estimated permanent longevity impact. To illustrate this issue, we experimented with using an approximation of lifelong health spending-by multiplying annual health spending times individual LE-and included this variable instead of annual health expenditure in the QALE models. The estimated effect of a 1€ increase over an individual's lifetime was 0.000044 QALE, that is, under 1 hr of life. The transformation required in this case is simply 1/0.000044 (= 22,727€), yielding a very similar cost per QALY as estimated with our approach. Fourth, although we have aimed in this study to provide a first empirical estimation of the cost per QALY in Spain, we acknowledge a degree of uncertainty around the magnitude of the health spending elasticity estimates that ought to be further explored and characterised.
Over and above the methodological complexities of estimating the actual cost per QALY, it is also worth noting that such information is only a proxy of the average opportunity cost of funding decisions. League tables and the identification of the specific intervention(s) that would be displaced for new interventions to be adopted arguably provide a better estimation of the true opportunity cost for each funding decision. However, league tables are generally not feasible, and most often it is unknown what activities will be displaced when imposing new costs to the system. Moreover, disinvestment may not imply that specific services are fully removed but instead that reductions in spending are imposed across different health services within the system. Therefore, the use of the average cost per QALY across the system provides a useful approximation of the opportunity costs of health care funding decisions.
The estimate provided in this paper suggests that the most commonly cited threshold value of 30,000€ per LY/QALY used in Spain is higher than the estimated threshold derived from the opportunity cost approach. The 30,000€ figure was not based on an empirical estimation but simply reflected the findings from a review of the Spanish economic evaluation literature showing that authors of published papers were likely to recommend adoption of the intervention under study when the ICER was below this value (Sacristán, Oliva, Del Llano, Prieto, & Pinto, 2002) . It is worth noting, though, that the analysis allowing for population weighting yielded an estimation similar to this figure. The question of whether or not to use weights in an analysis aimed at estimating causal effects is not straightforward. Solon et al., 2015 discuss several distinct reasons for which one may (or may not, as they stressed) prefer to use weights. One motive to use weights is to correct for heteroskedastic error terms and thus improve precision in the estimation of coefficients. As the authors noted, however, harming the precision of estimation with population weighting is quite a common phenomenon; in our study, robust standard errors were found to be smaller in the unweighted regression. Another argued motivation for weighting is to identify population average partial effects in the presence of heterogeneous effects. If the effect of health spending on health is smaller in larger regions, then weighted estimations that place greater weight on more populous regions will tend to estimate smaller effects than unweighted estimations. The authors emphasise that this raises the question of whether one might want to weight in order to identify a particular average of heterogeneous effects. In our case, given that the estimation of the cost-effectiveness threshold is to pertain to each of the 17 regional health services in Spain, we believe the estimation that gives equal weight to each region to more appropriate reflects the complex devolved nature of the Spanish NHS.
In this paper, we have aimed to generate information on the cost per QALY of the SNHS on the basis that, under fixed budget constraints that characterise most health services, information on the opportunity cost is what matters to make allocation decisions. A serious danger with using such approach alone, however, is that it might perpetuate the belief that the opportunity cost threshold reflects the marginal benefits of health care and decision makers would not be made aware of the series of technologies whose benefits offset their costs according to society's view. A society-value threshold allows for the identification of such interventions, and this information might have implications for the size of the budget. Furthermore, budgets might not always be fixed, especially when new tax revenue becomes available for the health care system. The opportunity costs of allocating new funds to health would then not fall within the NHS but across other alternative uses of public spending. Therefore, the estimates provided in this paper will not be relevant to guide such decisions. Society's value of health gains would arguably better reflect the strengths of preferences across different alternatives of consumptions of the public, providing a more relevant threshold reference. There are some previous studies within the Spanish context that have used the willingness to pay (WTP) approach to inform a cost-effectiveness threshold (Abellán Perpiñán et al., 2011; Donaldson et al., 2010; Martín-Fernández et al., 2014; Pinto-Prades, Loomes, & Brey, 2009 ). The finding of these studies are characterised by the sensitivity of the WTP values to the assumptions and techniques applied in the analyses. Further work to overcome these limitations on the societal valuation of a QALY is required.
Furthermore, the threshold defined by the cost per QALY is a dynamic figure that needs to be frequently updated to account for changes in the budget and efficiency over time. The identification and/or development of new routinely collected data sources is required to refine and update the estimates currently provided, and further work is needed to account for any remaining source of endogeneity and to explicitly address uncertainties around the estimated values. 
APPENDIX B: MEAN VALUES AND COEFFICIENTS OF COVARIATES
